4D Molecular Therapeutics, Inc. (FDMT) Operating cash flow 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$109.1MFY2025 · since FY2019: -$36.7M → -$109.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$109.1M | +18.9% |
| FY2024 | -$134.6M | -77.6% |
| FY2023 | -$75.8M | +12.6% |
| FY2022 | -$86.7M | -25.4% |
| FY2021 | -$69.1M | -35.8% |
| FY2020 | -$50.9M | -38.7% |
| FY2019 | -$36.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice